TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26876564

Group type: EXPERIMENTAL
Intervention: Bilateral deep brain stimulation (DBS) of the dentato-rubro-thalamic tract (DRT) and subthalamic nucleus (STN)
Number of subjects: 2
Study: 26877119

Group type: EXPERIMENTAL
Intervention: Exposure treatment guided by the therapist
Number of subjects: 493
Study: 26879105

Group type: EXPERIMENTAL
Intervention: Higher energy density (ED) meals (142%) with larger portion sizes (200%)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Lower energy density (ED) meals (100%) with smaller portion sizes (100%)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Portion size (100%, 150%, 200%)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Energy density (100% vs 142%)
Number of subjects: 120
Study: 26879222

Group type: EXPERIMENTAL
Intervention: Mindful Eating Questionnaire (MEQ)
Number of subjects: 0
Study: 26879467

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS) incorporating ethmoidectomy without frontal sinusotomy
Number of subjects: 226

Group type: COMPARATOR
Intervention: Endoscopic sinus surgery (ESS) incorporating frontal sinusotomy
Number of subjects: 226
Study: 26879849

Group type: EXPERIMENTAL
Intervention: Malaria in pregnancy (MiP)
Number of subjects: 832
Study: 26879979

Group type: EXPERIMENTAL
Intervention: Presumed sarcoidosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 26880104

Group type: EXPERIMENTAL
Intervention: Pentraxin-3 (PTX3)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Procalcitonin
Number of subjects: 135

Group type: COMPARATOR
Intervention: C-reactive protein
Number of subjects: 135
Study: 26880668

Group type: EXPERIMENTAL
Intervention: Extended prediction rule including age >75 years, peripheral oedema, and systolic murmur
Number of subjects: 30

Group type: COMPARATOR
Intervention: Original prediction rule
Number of subjects: 30
Study: 26880670

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: 1-year follow-up on major events
Number of subjects: 4000
Study: 26880867

Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiation with DC injections (50 Gy of external beam radiation in 25 fractions, 4 intratumoral injections of DCs)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiation with DC injections
Number of subjects: 18
Study: 26881241

Group type: EXPERIMENTAL
Intervention: One-year lifestyle intervention programme inducing substantial weight loss (>0.5 BMI standard deviation scores) in 40 children
Number of subjects: 80

Group type: COMPARATOR
Intervention: No weight loss in another 40 children (control group)
Number of subjects: 80
Study: 26881370

Group type: COMPARATOR
Intervention: Interstitial lung abnormalities in FHS
Number of subjects: 10691

Group type: COMPARATOR
Intervention: Interstitial lung abnormalities in AGES-Reykjavik
Number of subjects: 10691

Group type: COMPARATOR
Intervention: Interstitial lung abnormalities in ECLIPSE
Number of subjects: 10691

Group type: COMPARATOR
Intervention: FHS cohort HR
Number of subjects: 10691

Group type: COMPARATOR
Intervention: AGES-Reykjavik cohort HR
Number of subjects: 10691

Group type: COMPARATOR
Intervention: COPDGene cohort HR
Number of subjects: 10691

Group type: COMPARATOR
Intervention: ECLIPSE cohort HR
Number of subjects: 10691
Study: 26882334

Group type: EXPERIMENTAL
Intervention: Daily snapshot ECG monitoring over 14 days
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Daily snapshot ECG monitoring over 28 days
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Daily snapshot ECG monitoring over 56 days
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Daily snapshot ECG monitoring over 112 days
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Daily snapshot ECG monitoring over 365 days
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Daily snapshot ECG monitoring over 365 days in patients with CHADS2 score ≥2
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Daily snapshot ECG monitoring over 365 days in patients with CHADS2 score of 1
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Daily snapshot ECG monitoring over 365 days in patients with AT/AF burden ≥0.044 hours/day
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Daily snapshot ECG monitoring over 365 days in patients with AT/AF burden <0.044 hours/day
Number of subjects: 370
Study: 26882402

Group type: EXPERIMENTAL
Intervention: Patients with COPD with positive cultures for potentially pathogenic micro-organisms
Number of subjects: 45

Group type: COMPARATOR
Intervention: Patients with COPD without positive cultures for potentially pathogenic micro-organisms
Number of subjects: 45
Study: 26882477

Group type: EXPERIMENTAL
Intervention: Bumps Detection test (prechemotherapy touch sensation deficits)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High CIPN subgroup (51% of patients)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-reported numbness/tingling in high CIPN subgroup
Number of subjects: 0
Study: 26882534

Group type: EXPERIMENTAL
Intervention: Patient-Centered Medical Home (PCMH)
Number of subjects: 136480

Group type: COMPARATOR
Intervention: Paper records
Number of subjects: 136480
Study: 26882907

Group type: EXPERIMENTAL
Intervention: Lymphocyte density
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Reduction in lymphocyte density at surgery
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Increase in lymphocyte density after chemotherapy
Number of subjects: 768
Study: 26882910

Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg administered orally
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (20 subjects, mean age 36.2 years)
Number of subjects: 10
Study: 26883498

Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 7243

Group type: COMPARATOR
Intervention: Clopidogrel (plus aspirin)
Number of subjects: 7243
Study: 26883583

Group type: EXPERIMENTAL
Intervention: Digital PCR (dPCR) assays for detection of recurrent mutations (XPO1 E571K, EZH2 Y641N, MYD88 L265P) in plasma cfDNA.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Detection of somatic mutations in cfDNA using dPCR.
Number of subjects: 0
Study: 26883693

Group type: EXPERIMENTAL
Intervention: Solithromycin
Number of subjects: 13
Study: 26884591

Group type: EXPERIMENTAL
Intervention: Entrectinib (pan-Trk inhibitor)
Number of subjects: 1
Study: 26885381

Group type: EXPERIMENTAL
Intervention: MLE Group (5 injection sites)
Number of subjects: 49

Group type: COMPARATOR
Intervention: non-MLE Group (4 injection sites)
Number of subjects: 49
Study: 26885675

Group type: EXPERIMENTAL
Intervention: boceprevir (BOC)-based triple therapy
Number of subjects: 10
Study: 26885686

Group type: EXPERIMENTAL
Intervention: Reduced-toxicity conditioning regimen with busulfan (100 mg/m²/d for 4 days), fludarabine (30 mg/m²/d for 5 days), and anti-thymocyte globulins (2.5 mg/kg/d for 2 days)
Number of subjects: 30
Study: 26885831

Group type: EXPERIMENTAL
Intervention: Late gadolinium enhancement cardiovascular magnetic resonance (LGE-CMR) imaging
Number of subjects: 235

Group type: COMPARATOR
Intervention: Coronary angiography
Number of subjects: 235
Study: 26885880

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (0, 400, 1000, 2000, or 4000 IU/day)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 323
Study: 26886785

Group type: EXPERIMENTAL
Intervention: Antibiotic exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibiotic stewardship programs
Number of subjects: 0
Study: 26887528

Group type: EXPERIMENTAL
Intervention: C-Pulse System
Number of subjects: 8
Study: 26888022

Group type: EXPERIMENTAL
Intervention: Imatinib therapy (retreatment) for a median of 16.9 months
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Imatinib withdrawal syndrome
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Longer duration of imatinib before discontinuation
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Minimal residual leukemia measured by digital polymerase chain reaction
Number of subjects: 90

Group type: COMPARATOR
Intervention: Imatinib discontinuation
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Newly developed or worsened musculoskeletal pain and pruritus
Number of subjects: 90
Study: 26888382

Group type: EXPERIMENTAL
Intervention: Incretin based drugs
Number of subjects: 972384

Group type: COMPARATOR
Intervention: Sulfonylureas
Number of subjects: 972384
Study: 26888535

Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor-α receptor 1 (TNF-α R1)
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: Interleukin 6 (IL-6)
Number of subjects: 1244

Group type: COMPARATOR
Intervention: Tumor necrosis factor-α receptor 1 (TNF-α R1) top quartile (>3.63 ng/L) vs bottom quartile (<2.24 ng/L)
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: Serum amyloid A, CD40 ligand, and monocyte chemoattractant protein 1
Number of subjects: 1244
Study: 26888594

Group type: EXPERIMENTAL
Intervention: Adaptive Servo-Ventilation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 26888714

Group type: EXPERIMENTAL
Intervention: 4-compartment model
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Dual-energy X-ray absorptiometry (DXA)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Total body water (TBW) via van Raaij equations
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: 3-compartment model
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Body density (Db) via air displacement plethysmography (ADP)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Skinfold thickness (SFT)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Air displacement plethysmography body density
Number of subjects: 41
Study: 26888800

Group type: EXPERIMENTAL
Intervention: Platelet inhibition (antiplatelet therapy)
Number of subjects: 201
Study: 26888975

Group type: EXPERIMENTAL
Intervention: Ranibizumab (Lucentis)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Aflibercept (Eylea)
Number of subjects: 89
Study: 26889973

Group type: EXPERIMENTAL
Intervention: EGFR TKI
Number of subjects: 293
Study: 26890209

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testing 25-hydroxyvitamin D levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment for patients found to be deficient or initiating ART or bisphosphonate therapy
Number of subjects: 0
Study: 26890637

Group type: EXPERIMENTAL
Intervention: 18F-FSPG
Number of subjects: 5

Group type: COMPARATOR
Intervention: 18F-FDG
Number of subjects: 5

Group type: COMPARATOR
Intervention: 18F-FET
Number of subjects: 5
Study: 26891037

Group type: EXPERIMENTAL
Intervention: Bryostatin-1 10 μg/m
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bryostatin-1 20 μg/m
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 26891040

Group type: EXPERIMENTAL
Intervention: Late life depression patients
Number of subjects: 18

Group type: COMPARATOR
Intervention: Normal elderly controls
Number of subjects: 18
Study: 26891080

Group type: EXPERIMENTAL
Intervention: Sample Confirmation Testing (SCT)
Number of subjects: 2820
Study: 26892084

Group type: EXPERIMENTAL
Intervention: Lotus Valve implantation
Number of subjects: 120
Study: 26892449

Group type: EXPERIMENTAL
Intervention: IVUS-MLA ≤2.83 mm²
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: IVUS-MLA ≤2.85 mm² in lesions with Vsub >30.7 cm³
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: IVUS-MLA ≤2.67 mm² in lesions with Vsub ≤30.7 cm³
Number of subjects: 101
Study: 26892510

Group type: EXPERIMENTAL
Intervention: Pooled cohort risk equation
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Maximum TBR values
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Agatston scores
Number of subjects: 74
Study: 26892585

Group type: EXPERIMENTAL
Intervention: Hypertensive subjects
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High levels of calcifications and/or inflammation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Local thoracic aortic inflammation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Calcifications of the thoracic descending aorta
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Inflammation of the ascending aorta
Number of subjects: 30
Study: 26892669

Group type: EXPERIMENTAL
Intervention: Vicorder
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 80
Study: 26892942

Group type: EXPERIMENTAL
Intervention: DMDD group
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Bipolar disorder group
Number of subjects: 71

Group type: COMPARATOR
Intervention: Healthy youths
Number of subjects: 71
Study: 26893034

Group type: EXPERIMENTAL
Intervention: Lung diffusing capacity for nitric oxide (DLNO)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lung diffusing capacity for carbon monoxide (DLCO)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Diffusive conductance (DMCO)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pulmonary capillary volume (VC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Measurement of DLNO
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Measurement of DLCO
Number of subjects: 60
Study: 26893128

Group type: EXPERIMENTAL
Intervention: Go! intervention (pedometer distribution, food labeling, persuasive messaging, integration of influential employees)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Go! intervention
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control group (clinic employees)
Number of subjects: 500
Study: 26893170

Group type: EXPERIMENTAL
Intervention: 10 mg oral melatonin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mg intravenous melatonin
Number of subjects: 12
Study: 26893500

Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 2830

Group type: COMPARATOR
Intervention: Prior failure of a tumour necrosis factor α antagonist
Number of subjects: 2830

Group type: COMPARATOR
Intervention: Narcotic analgesic use
Number of subjects: 2830

Group type: COMPARATOR
Intervention: Younger age
Number of subjects: 2830

Group type: COMPARATOR
Intervention: Corticosteroid use
Number of subjects: 2830
Study: 26894920

Group type: EXPERIMENTAL
Intervention: Renal transplantation
Number of subjects: 11
Study: 26895374

Group type: EXPERIMENTAL
Intervention: Higher levels of parental warmth
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: General parenting dimensions (including warmth)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Program completion
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Mean BMI change
Number of subjects: 44
Study: 26895792

Group type: EXPERIMENTAL
Intervention: Mean HbA1c increase by 1 percentage point
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Age and mean HbA1c combined
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Final models including all significant risk factors
Number of subjects: 0
Study: 26895876

Group type: EXPERIMENTAL
Intervention: Birthweight (BW) in grams
Number of subjects: 10652

Group type: EXPERIMENTAL
Intervention: Gestational age (GA) in days
Number of subjects: 10652
Study: 26895885

Group type: EXPERIMENTAL
Intervention: Sensor-Augmented Pump Use
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 26895949

Group type: EXPERIMENTAL
Intervention: GH replacement therapy for 6 months in the GH Rx group, dosage titrated to achieve normal IGF-1 levels.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Non-GH replacement therapy in the non-GH Rx group.
Number of subjects: 22

Group type: COMPARATOR
Intervention: GHD patients (22) vs healthy controls (44).
Number of subjects: 22
Study: 26896024

Group type: EXPERIMENTAL
Intervention: Multi-component care transitions programs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Focus groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed-methods approach
Number of subjects: 0
Study: 26896370

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch
Number of subjects: 99
Study: 26896466

Group type: EXPERIMENTAL
Intervention: Galectin-3
Number of subjects: 583
Study: 26896684

Group type: EXPERIMENTAL
Intervention: Shanchol™ stored at 2-8°C (Group A)
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Shanchol™ stored at 25°C (Group B)
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Shanchol™ stored at 37°C (Group C)
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Shanchol™ stored at 42°C (Group D)
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: All groups (A-D)
Number of subjects: 580
Study: 26896702

Group type: EXPERIMENTAL
Intervention: Bronchial genomic classifier
Number of subjects: 222

Group type: COMPARATOR
Intervention: Invasive procedures after inconclusive bronchoscopy
Number of subjects: 222
Study: 26897304

Group type: EXPERIMENTAL
Intervention: Nasal filter (Rhinix)
Number of subjects: 1073
Study: 26897675

Group type: EXPERIMENTAL
Intervention: High on-treatment platelet reactivity (HPR) defined as platelet reactivity >208 P2Y12 reaction unit
Number of subjects: 773

Group type: EXPERIMENTAL
Intervention: High on-treatment platelet reactivity (HPR)
Number of subjects: 773

Group type: EXPERIMENTAL
Intervention: Presence of angiographic calcium
Number of subjects: 773
Study: 26897966

Group type: EXPERIMENTAL
Intervention: Endoscopic radiofrequency ablation (RFA)
Number of subjects: 12
Study: 26898568

Group type: COMPARATOR
Intervention: DTG 50 mg q24h alone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: DTG 50 mg q24h + CBZ 300 mg q12h
Number of subjects: 16
Study: 26898607

Group type: EXPERIMENTAL
Intervention: Sorafenib 400mg twice daily and erlotinib 150mg daily in 28-day cycles
Number of subjects: 46
Study: 26899539

Group type: EXPERIMENTAL
Intervention: Atazanavir/Ritonavir (ATV/r)
Number of subjects: 517
Study: 26899665

Group type: EXPERIMENTAL
Intervention: Brivaracetam (Briviact)
Number of subjects: 0
Study: 26900584

Group type: EXPERIMENTAL
Intervention: Paired associative stimulation (PAS)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Healthy controls (age/gender-matched)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: NMDAR encephalitis patients
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Follow-up assessments in six patients
Number of subjects: 34
Study: 26900642

Group type: EXPERIMENTAL
Intervention: Leptin replacement (6–12 months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (age-, gender-, race-, and ethnicity-matched)
Number of subjects: 60
Study: 26900869

Group type: EXPERIMENTAL
Intervention: Moderate/severe peri-implantitis
Number of subjects: 596
Study: 26901037

Group type: EXPERIMENTAL
Intervention: Total Intravenous Anaesthesia with Propofol (TIVA)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Inhalational Anaesthesia with Sevoflurane
Number of subjects: 190
Study: 26901102

Group type: EXPERIMENTAL
Intervention: Yoga/Stretching (YS) with Protein-Pacing (PP) diet
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Functional Resistance (FR) training with Protein-Pacing (PP) diet
Number of subjects: 27

Group type: COMPARATOR
Intervention: Protein-Pacing (PP) diet only
Number of subjects: 27
Study: 26901163

Group type: EXPERIMENTAL
Intervention: Sorafenib treatment
Number of subjects: 3202

Group type: EXPERIMENTAL
Intervention: Locoregional therapies before sorafenib
Number of subjects: 3202

Group type: EXPERIMENTAL
Intervention: Sorafenib treatment duration
Number of subjects: 3202
Study: 26901787

Group type: EXPERIMENTAL
Intervention: Intramyocardially injected autologous bone marrow-derived mesenchymal stromal cells (MSCs) (mean: 61.5×10(6) cells per patient) injected into 10-16 viable sites at the border of the LV scar via a NOGA-guided catheter.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intramyocardially injected autologous bone marrow-derived mesenchymal stromal cells (MSCs)
Number of subjects: 10
Study: 26902643

Group type: EXPERIMENTAL
Intervention: Morphine consumption
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Linear regression model including age and 9 SNPs in ESR1, OPRM1, and COMT
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Minimal model including 3 SNPs in ESR1, OPRM1, and COMT
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Interaction between rs4680 in COMT and rs4986936 in ESR1
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: SNPs rs677830 and rs540825 of OPRM1 and rs9340799 of ESR1
Number of subjects: 200
Study: 26902761

Group type: EXPERIMENTAL
Intervention: BMS-663068 400 mg BID
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: BMS-663068 600 mg BID
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: BMS-663068 800 mg BID
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: BMS-663068 600 mg QD
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: BMS-663068 1200 mg QD
Number of subjects: 244
Study: 26902828

Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Osimertinib (20-240 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Osimertinib (20 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 0
Study: 26903002

Group type: EXPERIMENTAL
Intervention: Reperfusion therapy
Number of subjects: 11986

Group type: EXPERIMENTAL
Intervention: Early aspirin administration
Number of subjects: 11986

Group type: EXPERIMENTAL
Intervention: Clopidogrel administration
Number of subjects: 11986
Study: 26903277

Group type: EXPERIMENTAL
Intervention: 1 g of ceftriaxone injection followed by 6 days of 400 mg of cefixime per day
Number of subjects: 37
Study: 26903305

Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA) using an electrical current of 0.8 mAmp at frequencies from 5-100 kHz
Number of subjects: 63
Study: 26903311

Group type: EXPERIMENTAL
Intervention: Panobinostat (20-60 mg) and epirubicin (75 mg/m² on day 5) given in 21-day cycles.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Panobinostat (50 mg, MTD) and epirubicin (75 mg/m² on day 5) given in 21-day cycles.
Number of subjects: 40